# A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed

Source: https://onco.cc/trials/nct06101134/  
OnCo record `nct06101134` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nivolumab, Relatlimab + nivolumab in melanoma, run by Bristol-Myers Squibb, active and no longer recruiting.

## Summary

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations is a phase 2 interventional study registered as NCT06101134 by Bristol-Myers Squibb, with 100 participants enrolled, started 2023-11-06 and due to reach its primary completion in 2025-04-10. Interventions recorded: relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab, nivolumab+rHuPH20. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06101134
- Phase: 2
- Setting: A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for Nivolumab + Relatlimab Fixed-dose Combination Subcutaneous Versus Nivolumab + Relatlimab Fixed-dose Combination Intravenous and Nivolumab Subcutaneous Versus Nivolumab Intravenous in Participants With Melanoma
- Sponsor: Bristol-Myers Squibb
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06101134: https://clinicaltrials.gov/study/NCT06101134

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Relatlimab + nivolumab](https://onco.cc/drugs/relatlimab-nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct06101134.json